Advertisement

The Indian Journal of Pediatrics

, Volume 85, Issue 4, pp 253–254 | Cite as

Growth Hormone Therapy and Lipid Profile

  • Rajni Sharma
EDITORIAL COMMENTARY
  • 89 Downloads

Recombinant Growth Hormone (GH) therapy is indicated to increase height in children with proven GH deficiency (GHD). It has also been found to benefit short children born small for gestational age (SGA) who fail to have catch-up growth by 2–4 y of age [1].

The effects of GH on linear growth in childhood are mediated by the secretion of Insulin-like-growth-factor-1 (IGF-1) from the liver and cartilage growth plates. Apart from this, GH has several metabolic actions in the body including those on body composition and lipid and glucose metabolism [2]. Due to its lipolytic effect, it leads to a decrease in body fat mass and proportionate increase in lean body mass. It inhibits de novo synthesis of lipids in the liver and also activates key enzymes in lipoprotein metabolism. GH has an intricate action on glucose metabolism; on one hand, it antagonizes the effect of insulin on the muscle and liver leading to decreased insulin sensitivity and hyperglycemia, while IGF-1 has insulin-like...

Notes

Compliance with Ethical Standards

Conflict of Interest

None.

References

  1. 1.
    Clayton PE, Cianfarani S, Czernichow P, Johannsson G, Rapaport R, Rogol A. Management of the child born small for gestational age through to adulthood: a consensus statement of the international societies of pediatric endocrinology and the growth hormone research society. J Clin Endocrinol Metab. 2007;92:804–10.CrossRefPubMedGoogle Scholar
  2. 2.
    Rothermel J, Reinehr T. Metabolic alterations in paediatric GH deficiency. Best Pract Res Clin Endocrinol Metab. 2016;30:757–70.CrossRefPubMedGoogle Scholar
  3. 3.
    Ranke MS, Price DA, Reiter EO. Adverse effects reported in KIGS. In: Wilton P, editor. Growth hormone therapy in pediatrics: 20 years of KIGS. Basel: Karger; 2007. p. 432–41.CrossRefGoogle Scholar
  4. 4.
    Zimmet P, Alberti KG, Kaufman F, et al; IDF Consensus Group. The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diabetes. 2007;8:299–306.CrossRefPubMedGoogle Scholar
  5. 5.
    Giovannini L, Tirabassi G, Muscogiuri G, Di Somma C, Colao A, Balercia G. Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk. Endocr J. 2015;62:1037–48.CrossRefPubMedGoogle Scholar
  6. 6.
    Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab. 2004;89:2192–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Meazza C, Elsedfy HH, Pagani S, Bozzola E, El Kholy M, Bozzola M. Metabolic parameters and adipokine profile in growth hormone deficient (GHD) children before and after 12-month GH treatment. Horm Metab Res. 2014;46:219–23.PubMedGoogle Scholar
  8. 8.
    Salerno M, Esposito V, Spinelli L, et al. Left ventricular mass and function in children with GH deficiency before and during 12 months GH replacement therapy. Clin Endocrinol. 2004;60:630–6.CrossRefGoogle Scholar
  9. 9.
    Lanes R, Gunczler P, Lopez E, Esaa S, Villaroel O, Revel-Chion R. Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone-deficient adolescents. J Clin Endocrinol Metab. 2001;86:1061–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Foster C, Burton A, Scholl J, Scott ML, Gunter V, McCormick K. Lipid patterns in treated growth hormone deficient children vs. short stature controls. J Pediatr Endocrinol Metab. 2014;27:909–14.CrossRefPubMedGoogle Scholar
  11. 11.
    Gleeson H, Barreto ES, Salvatori R, et al. Metabolic effects of growth hormone (GH) replacement in children and adolescents with severe isolated GH deficiency due to a GHRH receptor mutation. Clin Endocrinol. 2007;66:466–74.Google Scholar
  12. 12.
    Sas T, Mulder P, Hokken-Koelega A. Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J Clin Endocrinol Metab. 2000;85:3786–92.PubMedGoogle Scholar
  13. 13.
    Kubo T, Furujo M, Takahashi K, et al. Effects of growth hormone treatment on lipid profiles. Indian J Pediatr. 2017;  https://doi.org/10.1007/s12098-017-2509-8.
  14. 14.
    Rudling M, Angelin B. Growth hormone reduces plasma cholesterol in LDL receptor-deficient mice. FASEB J. 2001;15:1350–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Claessen KM, Appelman-Dijkstra NM, Adoptie DM, et al. Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab. 2013;98:352–61.CrossRefPubMedGoogle Scholar
  16. 16.
    Carel JC, Ecosse E, Landier F, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab. 2012;97:416–25.CrossRefPubMedGoogle Scholar
  17. 17.
    van der Steen M, Kerkhof GF, Smeets CCJ, Hokken-Koelega ACS. Cardiovascular risk factors and carotid intima media thickness in young adults born small for gestational age after cessation of growth hormone treatment: a 5-year longitudinal study. Lancet Diabetes Endocrinol. 2017;5:975–85.CrossRefPubMedGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2018

Authors and Affiliations

  1. 1.Division of Pediatric Endocrinology, Department of PediatricsAIIMSNew DelhiIndia

Personalised recommendations